Skip to main content

Table 3 Clinicopathological features of the 389 patients with primary breast carcinomas according to methylation status of NDRG1

From: Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer

Clinical Samples NDRG1  
Data n M ORs (95%CIs) P value
Menopausal status     
Pre- 162 51 1.0  
Post- 227 70 1.86(0.84-4.14) 0.126
Tumor size     
<1.0 7 3 1.0  
1.0-1.9 136 45 0.84(0.14-4.88) 0.842
2-3 200 61 0.64(0.11-3.69) 0.615
≥3.1 46 12 0.55(0.08-3.59) 0.535
Histological grade     
Well 150 35 1.0  
Moderate 207 72 1.89(1.20-3.20) 0.017
Poor 32 14 2.96(1.19-7.39) 0.020
Metastasis     
Negative 232 63 1.0  
Positive 157 58 1.94(1.10-3.40) 0.021
Lymph node invasion     
Negative 86 20 1.0  
Positive 303 101 2.22(1.19-4.11) 0.011
TNM stage     
0/I 87 20 1.0  
II 173 53 1.88(0.96-3.67) 0.064
III/IV 129 48 2.82(1.41-5.62) 0.003
p53 mutation     
Wild 160 50 1.0  
Mutant 229 71 1.04(0.64-1.70) 0.865
HER2 status     
Negative 270 86 1.0  
Positive 119 35 0.83(0.49-1.39) 0.472
Ki67 proliferation index     
<10% 93 32 1.0  
10%-32% 152 44 0.66(0.35-1.25) 0.200
33% 144 45 0.78(0.41-1.48) 0.441